Fluconatsoli

Fluconatsoli, commonly referred to as fluconazole, is an antifungal medication in the azole class, specifically a triazole. It works by inhibiting fungal cytochrome P450 14α-demethylase, an enzyme required for converting lanosterol to ergosterol. The resulting disruption of ergosterol synthesis compromises fungal cell membranes and inhibits growth.

The drug has broad activity against Candida species and Cryptococcus, with good activity against several other yeasts. It has limited activity against molds such as Aspergillus and limited effectiveness against many dermatophytes. Fluconazole penetrates body tissues well, including the central nervous system, and is available in oral and intravenous forms.

Indications include mucosal candidiasis (oral and esophageal), vulvovaginal candidiasis, cryptococcal meningitis, and certain other invasive Candida infections. It is also used for prophylaxis in some immunocompromised patients. Dosing depends on the site and severity of infection and on renal function. The oral bioavailability is high, and both oral and IV formulations are commonly used.

Pharmacokinetics and administration: fluconazole is well absorbed orally, distributes widely, and is primarily excreted unchanged in the urine, necessitating renal dose adjustments. The half-life is relatively long, allowing once-daily dosing in many cases. It can interact with other drugs and may affect levels of coumarins, phenytoin, theophylline, and cyclosporine.

Safety and adverse effects: common side effects include nausea, abdominal pain, and headaches. Hepatic toxicity and severe skin reactions are rare but important considerations. It should be used with caution in pregnancy unless clearly needed, and liver or kidney function should be monitored during prolonged therapy.